Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: MrChaos who wrote (46009)	5/5/2018 9:46:59 PM
From: idahoranch1	5 Recommendations of 63276

It’s on my list of concerns, somewhere below WW3 and a collapse of the internet, another dust bowl and food shortage. All are possible, but at least with the phase lll trial we have a lot of data to put into the mix, it’s not just a shot in the dark. 132 shrinks tumors in a significant % of patients in several indications and a very good safety profile. For now, mostly looking forward to the release of the abstracts on May 16th. That’s going to be an interesting bit of information to add to what we have.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next